ApicHope Pharmaceutical Group Co., Ltd. (SHE:300723)

Market Cap	16.59B
Revenue (ttm)	1.89B
Net Income (ttm)	-343.88M
Shares Out	449.03M
EPS (ttm)	-0.78
PE Ratio	n/a
Forward PE	n/a
Dividend	0.21 (0.57%)
Ex-Dividend Date	Jun 3, 2024

Volume	17,808,650
Average Volume	16,427,003
Open	39.36
Previous Close	38.69
Day's Range	35.65 - 39.80
52-Week Range	12.74 - 42.42
Beta	0.59
RSI	66.73
Earnings Date	Apr 25, 2025

About SHE:300723

ApicHope Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical drugs. Its pediatric medicines include fuganlin and yiqi jianpi oral liquid, carboxymestrine oral solution, and xiaoer kechuanling oral liquid products; and clindamycin hydrochloride palmitate dispersible tablet, acetylguitaricin dry suspension, qinxiangqingjie oral liquid, levocetirizine hydrochloride drop, epstein hydrochloride granule, clindamycin hydrochloride palmitate granule, clindamycin...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 1,676
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300723

Financial Performance

In 2023, SHE:300723's revenue was 2.50 billion, an increase of 9.79% compared to the previous year's 2.28 billion. Earnings were 184.61 million, a decrease of -36.49%.